NBME Form 27 Practice Test

Glipizide and other sulfonylureas primarily lead to hypoglycemia by stimulating the release of endogenous insulin from the pancreatic beta cells. By binding to specific receptors (the sulfonylurea receptor) on these cells, they promote the closure of ATP-sensitive potassium channels. This action causes depolarization of the beta cell membrane, triggering the influx of calcium ions. The increase in intracellular calcium levels then stimulates the exocytosis of insulin granules, resulting in a greater release of insulin into the bloodstream.

This mechanism is particularly effective in lowering blood glucose levels; however, it also puts patients at risk for hypoglycemia, especially if they do not consume enough carbohydrates or if they engage in excessive physical activity. The use of sulfonylureas can lead to secretion of insulin irrespective of the current blood glucose level, which contributes to the potential for hypoglycemia when blood sugar levels are already low or not elevated.

Understanding this mechanism is crucial as it highlights the importance of monitoring blood glucose levels and adjusting dietary and physical activity patterns when using these medications to minimize the risk of hypoglycemic episodes.